{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:33:15Z","timestamp":1760099595613},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1016\/j.jcv.2004.09.002","type":"journal-article","created":{"date-parts":[[2004,10,13]],"date-time":"2004-10-13T17:53:41Z","timestamp":1097690021000},"page":"55-62","source":"Crossref","is-referenced-by-count":4,"special_numbering":"S1","title":["Phase II placebo-controlled study of V-1 Immunitor as a therapeutic modality for treatment of HIV"],"prefix":"10.1016","volume":"31","author":[{"given":"Aldar S.","family":"Bourinbaiar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vichai","family":"Jirathitikal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orapun","family":"Metadilogkul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penpit","family":"Sooksathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prapaphan","family":"Paiboon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siriwan","family":"Aemsri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Promdevich","family":"Prapai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotchakan","family":"Chaodon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2004.09.002_bib1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1258\/0956462981921125","article-title":"The recent impact of antiretroviral combination therapy on CD4 counts, AIDS and death in HIV-infected persons: routine HIV surveillance in Scotland","volume":"9","author":"Allardice","year":"1998","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.jcv.2004.09.002_bib2","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1089\/088922202320935438","article-title":"Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy","volume":"18","author":"Asjo","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.jcv.2004.09.002_bib3","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nri1107","article-title":"Therapeutic vaccines against HIV need international partnerships","volume":"3","author":"Autran","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jcv.2004.09.002_bib4","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1097\/00002030-200107270-00006","article-title":"Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults","volume":"15","author":"Bartlett","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2004.09.002_bib5","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2174\/1381612033454685","article-title":"Low-cost anti-HIV compounds: potential application for AIDS therapy in developing countries","volume":"9","author":"Bourinbaiar","year":"2003","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jcv.2004.09.002_bib6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1089\/088282403771926274","article-title":"Mucosal AIDS vaccines","volume":"16","author":"Bourinbaiar","year":"2003","journal-title":"Viral Immunol"},{"key":"10.1016\/j.jcv.2004.09.002_bib7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0306-9877(94)90034-5","article-title":"Mucosal origin of AIDS","volume":"42","author":"Bourinbaiar","year":"1994","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.jcv.2004.09.002_bib8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0140-6736(97)04161-5","article-title":"Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group","volume":"351","author":"Cameron","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2004.09.002_bib9","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1128\/CDLI.7.5.728-733.2000","article-title":"A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected Thai subjects with CD4-cell counts of >300","volume":"7","author":"Churdboonchart","year":"2000","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.jcv.2004.09.002_bib10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00002030-199904160-00001","article-title":"HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy","volume":"13","author":"Deeks","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2004.09.002_bib11","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1128\/CDLI.8.2.468-469.2001","article-title":"Effectiveness of Remune","volume":"8","author":"Glidden","year":"2001","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.jcv.2004.09.002_bib12","first-page":"326","article-title":"The effects on survival of early treatment of human immunodeficiency virus infection","author":"Graham","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcv.2004.09.002_bib13","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1056\/NEJM199202133260703","article-title":"A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study","volume":"326","author":"Hamilton","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcv.2004.09.002_bib14","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199709113371101","article-title":"A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team","volume":"337","author":"Hammer","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcv.2004.09.002_bib15","doi-asserted-by":"crossref","unstructured":"HIV Surrogate Marker Collaborative Group. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. AIDS Res Hum Retroviruses 2000;16:1123\u201333.","DOI":"10.1089\/088922200414965"},{"key":"10.1016\/j.jcv.2004.09.002_bib16","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/00002030-199814000-00014","article-title":"CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group","volume":"12","author":"Hughes","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2004.09.002_bib17","first-page":"17","article-title":"Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy","author":"Hunt","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2004.09.002_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1310\/EP0E-PCNM-KRBN-2GF3","article-title":"Safety and efficacy of an oral HIV vaccine (V-1 Immunitor) in AIDS patients at various stages of the disease","volume":"3","author":"Jirathitikal","year":"2002","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.jcv.2004.09.002_bib19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/sj.ejcn.1601756","article-title":"Increased body weight and improved quality of life in AIDS patients following V-1 Immunitor administration","volume":"58","author":"Jirathitikal","year":"2004","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.jcv.2004.09.002_bib20","first-page":"76","article-title":"Normalization of elevated liver enzymes due to V-1 Immunitor therapy","volume":"6","author":"Jirathitikal","year":"2003","journal-title":"Electron J Biotechnol"},{"key":"10.1016\/j.jcv.2004.09.002_bib21","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0264-410X(02)00570-4","article-title":"V-1 Immunitor: oral AIDS vaccine with therapeutic and prophylactic potential","volume":"21","author":"Jirathitikal","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.jcv.2004.09.002_bib22","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1001\/jama.284.17.2193","article-title":"Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300\u00d7106L\u22121 to 549\u00d7106L\u22121 CD4 cell counts: a randomized controlled trial","volume":"284","author":"Kahn","year":"2000","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.jcv.2004.09.002_bib23","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1086\/315469","article-title":"Disease progression and survival with human immunodeficiency virus type 1 subtype E infection among female sex workers in Thailand","volume":"181","author":"Kilmarx","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcv.2004.09.002_bib24","first-page":"252","article-title":"Therapeutic vaccination for HIV disease","volume":"13","author":"Laurence","year":"2003","journal-title":"AIDS Read"},{"key":"10.1016\/j.jcv.2004.09.002_bib25","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1086\/338929","article-title":"Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen","volume":"185","author":"Le Moing","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcv.2004.09.002_bib26","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0264-410X(02)00569-8","article-title":"Therapeutic vaccination for future management of HIV\/AIDS","volume":"21","author":"Lisziewicz","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.jcv.2004.09.002_bib27","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1097\/00002030-199710000-00009","article-title":"The influence of drug use patterns on the rate of CD4+ lymphocyte decline among HIV-1-infected injecting drug users","volume":"11","author":"Lyles","year":"1997","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2004.09.002_bib28","doi-asserted-by":"crossref","first-page":"946","DOI":"10.7326\/0003-4819-126-12-199706150-00003","article-title":"Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection","volume":"126","author":"Mellors","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jcv.2004.09.002_bib29","unstructured":"Metadilogkul O, Jirathitikal V, Bourinbaiar AS. Serodeconversion of HIV antibody-positive AIDS patients after treatment with V-1 Immunitor. In: Bourinbaiar AS, editor. AIDS vaccines and related topics. Research Signpost (Kerala, India); 2004. p. 76\u201388."},{"key":"10.1016\/j.jcv.2004.09.002_bib30","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1310\/WVL6-8CGL-MGHH-6GHX","article-title":"Survival of end-stage patients receiving V-1 Immunitor","volume":"3","author":"Metadilogkul","year":"2002","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.jcv.2004.09.002_bib31","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJM199602153340703","article-title":"Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS Veterans Affairs Cooperative Study Group on AIDS","volume":"334","author":"O\u2019Brien","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcv.2004.09.002_bib32","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-138-8-200304150-00007","article-title":"HIV Outpatient Study Investigators. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata","volume":"138","author":"Palella","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jcv.2004.09.002_bib33","first-page":"260","article-title":"V-1 Immunitor","volume":"3","author":"Phanuphak","year":"2002","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.jcv.2004.09.002_bib34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00042560-199803010-00009","article-title":"Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group","volume":"17","author":"Phillips","year":"1998","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"10.1016\/j.jcv.2004.09.002_bib35","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1056\/NEJM199106133242401","article-title":"A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection, Military Medical Consortium for Applied Retroviral Research","volume":"321","author":"Redfield","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcv.2004.09.002_bib36","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00126334-200312010-00004","article-title":"Neaton JD. Grade 4 events are as important as AIDS events in the era of HAART","volume":"34","author":"Reisler","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jcv.2004.09.002_bib37","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/00002030-199904160-00007","article-title":"Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen","volume":"13","author":"Renaud","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2004.09.002_bib38","first-page":"259","article-title":"Editorial comments","volume":"3","author":"Sabin","year":"2002","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.jcv.2004.09.002_bib39","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1046\/j.1468-1293.2001.00080.x","article-title":"Therapeutic vaccination (p24-VLP) of patients with advanced HIV-1 infection in the pre-HAART era does not alter CD4 cell decline","volume":"2","author":"Smith","year":"2001","journal-title":"HIV Med"},{"key":"10.1016\/j.jcv.2004.09.002_bib40","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1086\/342603","article-title":"Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies","volume":"186","author":"Tebas","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcv.2004.09.002_bib41","doi-asserted-by":"crossref","unstructured":"The AVANTI and INCAS Study Groups. Highly active antiretroviral therapy including protease inhibitors does not confer a unique CD4 cell benefit. AIDS 2000;14(10):1383\u201388.","DOI":"10.1097\/00002030-200007070-00011"},{"key":"10.1016\/j.jcv.2004.09.002_bib42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1310\/YN11-XJ4L-9YHF-19E4","article-title":"Virological and immunological response to HAART therapy in a community-based cohort of HIV-1-positive individuals","volume":"2","author":"Touloumi","year":"2001","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.jcv.2004.09.002_bib43","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00042560-200206010-00004","article-title":"Discordant increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy","volume":"30","author":"Wood","year":"2002","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653204002239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653204002239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T14:38:57Z","timestamp":1624718337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653204002239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":43,"alternative-id":["S1386653204002239"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2004.09.002","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}